Recent Research Analysts’ Ratings Updates for Harmony Biosciences (HRMY)

Several analysts have recently updated their ratings and price targets for Harmony Biosciences (NASDAQ: HRMY):

• 12/29/2025 – Harmony Biosciences had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Harmony Biosciences had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Harmony Biosciences had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/13/2025 – Harmony Biosciences was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 12/8/2025 – Harmony Biosciences had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/3/2025 – Harmony Biosciences had its “buy” rating reaffirmed by analysts at HC Wainwright.
• 12/1/2025 – Harmony Biosciences had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Harmony Biosciences had its price target raised by analysts at Mizuho from $39.00 to $46.00. They now have an “outperform” rating on the stock.
• 11/24/2025 – Harmony Biosciences had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Harmony Biosciences had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $62.00 price target on the stock.
• 11/24/2025 – Harmony Biosciences had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
• 11/24/2025 – Harmony Biosciences had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $42.00 price target on the stock.
• 11/17/2025 – Harmony Biosciences had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/11/2025 – Harmony Biosciences had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 11/8/2025 – Harmony Biosciences was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/6/2025 – Harmony Biosciences had its price target raised by analysts at Mizuho from $36.00 to $39.00. They now have an “outperform” rating on the stock.
• 11/5/2025 – Harmony Biosciences had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.

Insider Activity

In other news, CEO Jeffrey M. Dayno sold 25,933 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $40.11, for a total value of $1,040,172.63. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 23.60% of the stock is owned by corporate insiders.

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.